Free Trial

Silverback Therapeutics (SBTX) Competitors

Silverback Therapeutics logo
$18.35 +0.48 (+2.69%)
As of 07/17/2025

SBTX vs. GMTX, CALT, ZYME, MENS, MBX, AVTE, NLTX, CYBN, BIOA, and VIRI

Should you be buying Silverback Therapeutics stock or one of its competitors? The main competitors of Silverback Therapeutics include Gemini Therapeutics (GMTX), Calliditas Therapeutics AB (publ) (CALT), Zymeworks (ZYME), Jyong Biotech (MENS), MBX Biosciences (MBX), Aerovate Therapeutics (AVTE), Neoleukin Therapeutics (NLTX), Cybin (CYBN), BioAge Labs (BIOA), and Virios Therapeutics (VIRI).

Silverback Therapeutics vs. Its Competitors

Silverback Therapeutics (NASDAQ:SBTX) and Gemini Therapeutics (NASDAQ:GMTX) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, earnings, analyst recommendations, dividends, institutional ownership, valuation and risk.

Silverback Therapeutics' return on equity of -29.62% beat Gemini Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Silverback TherapeuticsN/A -29.62% -28.20%
Gemini Therapeutics N/A -38.78%-35.88%

Gemini Therapeutics is trading at a lower price-to-earnings ratio than Silverback Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Silverback TherapeuticsN/AN/A-$89.48M-$2.42-7.58
Gemini TherapeuticsN/AN/A-$71.87M-$1.00-57.79

74.9% of Silverback Therapeutics shares are owned by institutional investors. Comparatively, 75.4% of Gemini Therapeutics shares are owned by institutional investors. 34.4% of Silverback Therapeutics shares are owned by company insiders. Comparatively, 12.9% of Gemini Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Silverback Therapeutics has a beta of 0.6, meaning that its stock price is 40% less volatile than the S&P 500. Comparatively, Gemini Therapeutics has a beta of -0.12, meaning that its stock price is 112% less volatile than the S&P 500.

In the previous week, Silverback Therapeutics and Silverback Therapeutics both had 1 articles in the media. Silverback Therapeutics' average media sentiment score of 0.75 beat Gemini Therapeutics' score of 0.00 indicating that Silverback Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Silverback Therapeutics
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Gemini Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Silverback Therapeutics beats Gemini Therapeutics on 6 of the 9 factors compared between the two stocks.

Get Silverback Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for SBTX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SBTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SBTX vs. The Competition

MetricSilverback TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$661.66M$816.26M$5.54B$9.41B
Dividend YieldN/A4.84%3.75%4.03%
P/E Ratio-7.581.4128.0119.82
Price / SalesN/A27.13432.7298.44
Price / CashN/A19.5636.1658.27
Price / Book2.486.878.125.65
Net Income-$89.48M-$4.17M$3.25B$257.91M
7 Day Performance2.06%0.03%0.97%2.09%
1 Month Performance23.82%2.12%7.36%11.13%
1 Year Performance75.68%2.14%31.31%18.40%

Silverback Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SBTX
Silverback Therapeutics
N/A$18.35
+2.7%
N/A+57.7%$661.66MN/A-7.5883News Coverage
High Trading Volume
GMTX
Gemini Therapeutics
N/A$57.74
+1.5%
N/A+19.7%$2.50BN/A-57.7430
CALT
Calliditas Therapeutics AB (publ)
N/A$40.00
flat
N/AN/A$1.19B$1.60B-21.62180
ZYME
Zymeworks
3.1252 of 5 stars
$12.95
-3.0%
$21.00
+62.2%
+43.1%$903.30M$93.38M-8.64460News Coverage
MENS
Jyong Biotech
N/A$10.98
-5.4%
N/AN/A$834.81MN/A0.0031Positive News
Gap Up
MBX
MBX Biosciences
2.3376 of 5 stars
$13.28
-4.3%
$37.50
+182.4%
N/A$444.37MN/A0.0036Analyst Forecast
AVTE
Aerovate Therapeutics
N/A$9.00
-8.4%
N/A-86.7%$260.87MN/A-3.0120High Trading Volume
NLTX
Neoleukin Therapeutics
N/A$22.26
+3.9%
N/A-49.2%$209.20MN/A-7.1690High Trading Volume
CYBN
Cybin
2.8641 of 5 stars
$7.45
-0.3%
$85.00
+1,040.9%
N/A$171.55MN/A-1.7050News Coverage
BIOA
BioAge Labs
N/A$4.48
-3.2%
N/AN/A$160.61MN/A0.00N/A
VIRI
Virios Therapeutics
0.1108 of 5 stars
$5.08
+6.7%
$5.00
-1.6%
+1,446.4%$97.83MN/A-18.815News Coverage
Gap Up

Related Companies and Tools


This page (NASDAQ:SBTX) was last updated on 7/18/2025 by MarketBeat.com Staff
From Our Partners